Clinical Trials Browser

Phase EARLY_PHASE1 × Lymphoma, Mantle-Cell × CF regimen × Clear all

NCT04767308 2021-02-23

Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Lymphoma, Mantle-Cell